CK Life Sciences Int'l., (Holdings) Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
1,925
- Stock Symbol
-
00775
- Investments
-
19
- Share Price
-
$0.07
- (As of Monday Closing)
CK Life Sciences Int'l., (Holdings) General Information
Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
Contact Information
Website
www.ck-lifesciences.comCorporate Office
- 2 Dai Fu Street
- Tai Po Industrial Estate
- Hong Kong
- Hong Kong
Corporate Office
- 2 Dai Fu Street
- Tai Po Industrial Estate
- Hong Kong
- Hong Kong
CK Life Sciences Int'l., (Holdings) Stock Performance
As of 16-Nov-2026, CK Life Sciences Int'l., (Holdings)’s stock price is $0.07. Its current market cap is $643M with 9.6B shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.07 | $0.06 - $0.12 | $643M | 9.6B | 3.47M |
CK Life Sciences Int'l., (Holdings) Financials Summary
As of 30-Jun-2026, CK Life Sciences Int'l., (Holdings) has a trailing 12-month revenue of $707M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,474,695 | 1,745,172 | 1,201,088 | 1,458,121 |
| Revenue | 706,613 | 693,948 | 707,739 | 679,856 |
| EBITDA | 39,657 | 60,669 | 61,124 | 78,114 |
| Net Income | (8,282) | (23,961) | (16,218) | 2,203 |
| Total Assets | 1,551,458 | 1,521,126 | 1,389,653 | 1,439,337 |
| Total Debt | 871,314 | 850,899 | 785,685 | 759,007 |
CK Life Sciences Int'l., (Holdings) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CK Life Sciences Int'l., (Holdings) Signals
CK Life Sciences Int'l., (Holdings) Investments & Acquisitions (19)
CK Life Sciences Int'l., (Holdings)’s most recent deal was a Early Stage VC with PharusDx for . The deal was made on 30-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PharusDx | 30-Apr-2025 | Early Stage VC | Biotechnology | ||
| PharusDx | 25-Jul-2022 | Early Stage VC | Biotechnology | ||
| Nangiloc Colignan Farm (Farm Assets) | 01-Dec-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Polynoma | 16-Nov-2017 | Merger/Acquisition | Drug Discovery | ||
| Optigen Ingredients | 01-Jan-2014 | Merger/Acquisition | Specialty Chemicals |
CK Life Sciences Int'l., (Holdings) ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
CK Life Sciences Int'l., (Holdings) Exits (6)
CK Life Sciences Int'l., (Holdings)’s most recent exit was on 16-Nov-2017 from Polynoma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Polynoma | 16-Nov-2017 | Completed |
|
||
| Optigen Ingredients | 01-Jan-2014 | Completed |
|
||
| WEX Pharmaceuticals | 05-May-2011 | Completed |
|
||
| WEX Pharmaceuticals | 18-Oct-2009 | Completed |
|
||
| WEX Pharmaceuticals | 17-Oct-2007 | PIPE | Completed |
CK Life Sciences Int'l., (Holdings) Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lipa Pharmaceuticals | Minto, Australia | 1995 | |
| Cheetham Salt | Melbourne, Australia | 1888 |
CK Life Sciences Int'l., (Holdings) FAQs
-
When was CK Life Sciences Int'l., (Holdings) founded?
CK Life Sciences Int'l., (Holdings) was founded in 1999.
-
Where is CK Life Sciences Int'l., (Holdings) headquartered?
CK Life Sciences Int'l., (Holdings) is headquartered in Hong Kong, Hong Kong.
-
What is the size of CK Life Sciences Int'l., (Holdings)?
CK Life Sciences Int'l., (Holdings) has 1,925 total employees.
-
What industry is CK Life Sciences Int'l., (Holdings) in?
CK Life Sciences Int'l., (Holdings)’s primary industry is Holding Companies.
-
Is CK Life Sciences Int'l., (Holdings) a private or public company?
CK Life Sciences Int'l., (Holdings) is a Public company.
-
What is CK Life Sciences Int'l., (Holdings)’s stock symbol?
The ticker symbol for CK Life Sciences Int'l., (Holdings) is 00775.
-
What is the current stock price of CK Life Sciences Int'l., (Holdings)?
As of 16-Nov-2026 the stock price of CK Life Sciences Int'l., (Holdings) is $0.07.
-
What is the current market cap of CK Life Sciences Int'l., (Holdings)?
The current market capitalization of CK Life Sciences Int'l., (Holdings) is $643M.
-
What is CK Life Sciences Int'l., (Holdings)’s current revenue?
The trailing twelve month revenue for CK Life Sciences Int'l., (Holdings) is $707M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process